We evaluated outcomes by treatment group in the EXSCEL trial for the 10 782 participants (73% of the trial population) with known cardiovascular (CV) disease (i.e. history of major clinical manifestation of coronary artery disease, ischemic cerebrovascular disease or atherosclerotic peripheral arterial disease). Cox proportional hazards were used to compare the impact of once-weekly exenatide with placebo therapy on MACE, all-cause death, CV-related death, myocardial infarction, stroke, hospitalisation for acute coronary syndrome (hACS) and hospitalisation for heart failure.
